176523-95-8 Usage
Description
Ethyl 3-Methylpiperidine-3-carboxylate hydrochloride is a chemical compound with a molecular formula C9H18ClNO2. It is a salt form of the ester ethyl 3-methylpiperidine-3-carboxylate, which is an intermediate in the synthesis of pharmaceuticals. This white crystalline solid is soluble in water and other polar solvents, and is commonly used for research and development purposes in the pharmaceutical industry.
Used in Pharmaceutical Industry:
Ethyl 3-Methylpiperidine-3-carboxylate hydrochloride is used as an intermediate in the synthesis of drugs for its potential role in creating various pharmaceutical compounds.
Used in Organic Chemistry:
Ethyl 3-Methylpiperidine-3-carboxylate hydrochloride is used as a reagent in organic chemistry for its ability to facilitate certain chemical reactions and processes.
Check Digit Verification of cas no
The CAS Registry Mumber 176523-95-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,6,5,2 and 3 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 176523-95:
(8*1)+(7*7)+(6*6)+(5*5)+(4*2)+(3*3)+(2*9)+(1*5)=158
158 % 10 = 8
So 176523-95-8 is a valid CAS Registry Number.
176523-95-8Relevant articles and documents
PHARMACOLOGICALLY ACTIVE ALICYCLIC-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
-
Page/Page column 29, (2018/10/19)
The present invention relates to new pyrazolo[l,5-a]pyrimidine derivatives of formula (I) or pharmaceutical ly acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof that serve as GABAB receptor positive allosteric modulators. The invention al so relates to the process for producing such compounds. The invention further relates to pharmaceutical compositions comprising such compounds optionally in combination with two or more different therapeutic agents and the use of such compounds in methods for treating diseases and conditions mediated and modulated by the GABAB receptor positive allosteric mechanism. The invention al so provides a method for manufacture of medicaments useful in the treatment of such disorders.